# REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

> **NCT00663416** · PHASE2 · TERMINATED · sponsor: **Stem Cell Therapeutics Corp.** · enrollment: 134 (estimated)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** NTx™-265: rhCG, then rEPO
- **DRUG:** Saline placebo

## Key facts

- **NCT ID:** NCT00663416
- **Lead sponsor:** Stem Cell Therapeutics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2008-10
- **Final completion:** 2009-01
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2009-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00663416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00663416, "REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00663416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*